Joachim Wernicke
Overview
Explore the profile of Joachim Wernicke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
1974
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Asiimwe A, Li J, Weerakkody G, Vangerow H, Delisle F, Benoit K, et al.
Curr Drug Saf
. 2013 Oct;
8(4):261-9.
PMID: 24102361
Background And Aims: The association between gastrointestinal (GI) bleeding and subsequent detection of GI cancer in patients using antiplatelet/anticoagulant medications is unclear. We investigated the association between the occurrence of...
2.
Skljarevski V, Zhang S, Iyengar S, DSouza D, Alaka K, Chappell A, et al.
Curr Drug ther
. 2012 Aug;
6(4):296-303.
PMID: 22876216
The primary objective of this study is to review the efficacy of duloxetine in treating chronic pain using the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT)...
3.
Crucitti A, Zhang Q, Nilsson M, Brecht S, Yang C, Wernicke J
Curr Med Res Opin
. 2010 Sep;
26(11):2579-88.
PMID: 20874076
Objective: Mood disorders are often associated with poor glycemic control, and antidepressant treatments for mood and pain disorders can alter plasma glucose levels in patients with diabetes. A previous meta-analysis...
4.
Fishbain D, Detke M, Wernicke J, Chappell A, Kajdasz D
Curr Med Res Opin
. 2008 Oct;
24(11):3105-15.
PMID: 18828958
Objective: Debate continues regarding whether onset of analgesia is faster than antidepressant effect in antidepressants with both properties. Duloxetine hydrochloride (from here on referred to as duloxetine) is effective in...
5.
Wernicke J, Acharya N, Strombom I, Gahimer J, DSouza D, DiPietro N, et al.
Curr Drug Saf
. 2008 Aug;
3(2):143-53.
PMID: 18690992
Objective: Review spontaneous reports and epidemiology of hepatic events associated with duloxetine. Methods: Spontaneous reports of adverse events potentially associated with hepatic injury were identified. Classification schemes were Clinical Significance...
6.
Wernicke J, Pangallo B, Wang F, Murray I, Henck J, Knadler M, et al.
Curr Drug Saf
. 2008 Aug;
3(2):132-42.
PMID: 18690991
Objective: Review nonclinical and clinical trial data for hepatic effects of duloxetine. Methods: Review studies of toxicology, metabolism, mitochondrial effects, and clinical trials. Results: Nonclinical studies revealed no treatment-related transaminase...
7.
Wernicke J, Lledo A, Raskin J, Kajdasz D, Wang F
Drug Saf
. 2007 May;
30(5):437-55.
PMID: 17472422
Background And Objective: In recent years, new classes of medication, such as the serotonin-noradrenaline reuptake inhibitors (SNRIs), have been developed for use in the treatment of major depressive disorder (MDD)....
8.
Gahimer J, Wernicke J, Yalcin I, Ossanna M, Wulster-Radcliffe M, Viktrup L
Curr Med Res Opin
. 2007 Jan;
23(1):175-84.
PMID: 17257478
Objective: The safety and tolerability of duloxetine for major depressive disorder (MDD), generalized anxiety disorder (GAD), diabetic peripheral neuropathic pain (DPNP), fibromyalgia, and lower urinary tract disorders (LUTD) (including female...
9.
Turk D, Dworkin R, Burke L, Gershon R, Rothman M, Scott J, et al.
Pain
. 2006 Oct;
125(3):208-215.
PMID: 17069973
No abstract available.
10.
Dworkin R, Turk D, Farrar J, Haythornthwaite J, Jensen M, Katz N, et al.
Pain
. 2004 Dec;
113(1-2):9-19.
PMID: 15621359
No abstract available.